MRNA Directional Report
Analysis based on market close March 31, 2026
Outlook
Neutral-to-bearish with a short-term pinning magnet toward $51-$52, but a clear structural downtrend in max pain suggests underlying weakness. Confidence: 5/10. The regime is conflicted: positive GEX supports a pin, but net negative premium flow and a falling MP ladder point to selling pressure.
Conflicts: Net premium -$49.4M (bearish), max pain ladder falls from $52 to $35 long-term, IV >80% obscures directional signals.
Regime Classification
Price Range Forecast
Key Levels
Dealer Positioning (GEX/DEX)
GEX: $+28.9M
DEX: +23.9M shares
Gamma flip: ~$25 (Approx โ based on put OI concentration of 16,149)
NTM gamma: Gamma flip ~$25 is irrelevant near-term; positive GEX from calls near $50-$53 drives pinning. A move below $48.5 would reduce pinning pressure; a move above $53 would accelerate dealer short-covering.
IV Analysis
IV vs VIX: IV 81.3% โ extremely elevated vs typical biotech/historical, offering rich premium for sellers.
Term structure: Humped โ peaks at May expirations (~75%), then flattens. Kink at 5/01 (72.4%) likely pricing April 30 earnings.
Skew: Extreme skew in long-dated, deep OTM puts (e.g., Dec '26 $85 Put IV 205%) โ potential for ratio spreads selling those strikes vs buying nearer-dated puts.
Flow Analysis
Net premium: -$49.4M bearish; P/C vol 0.85, P/C OI 0.99.
Directional prints: $53C 3/27 vol 155 vs OI 16,178 โ likely closing/selling against existing long OI. $40P vol 104 vs OI 14,290 โ could be rolling or closing.
Unusual: **Deep OTM Put Sales**: Massive premium in Dec '26 $85P ($16.5M) and $135P ($7.1M) โ likely institutional tail-risk hedging or financing trades, not directional.
Risks & Catalysts
Strategy Viability
| Strategy | Edge | Best Setup | Primary Risk |
|---|---|---|---|
| Long stock | Weak | N/A | Bearish MP trend and negative net flow oppose. |
| Short stock | Moderate-Weak | N/A | Near-term pinning creates headwinds; better expressed via options. |
| Covered call | Moderate-Strong | Own stock, sell $53C or $55C 4/10 or 4/17. | Stock pinned below strike; upside capped. |
| Cash-secured put / put spread | Moderate-Strong | Sell $45/$40 put spread 4/17 (below 1w EM low). | Break of pin below $46.24. |
| Long calls | Weak | N/A | High IV expensive; pinning limits upside. |
| Long puts / bear put spread | Moderate | Buy $50/$45 put spread 4/17 or 5/01 (earnings). | Pinning eats theta; need break below $48.5. |
| Iron condor | Moderate | $45P/$40P x $53C/$56C 4/17 (outside 1w EM bounds). | GEX positive but VIX proxy (IV) >28, and range is wide. |
| Calendar/diagonal | Moderate | Sell 5/01 $51C (IV 72.4%), buy 4/17 $51C (IV 66.0%) โ reverse calendar for pin breakdown. | Pin holds through April expiry. |
| PMCC / LEAPS diagonal | Moderate | Buy Jan '27 $35C, sell Apr/May $51-$53 calls against it. | Long-dated IV still high; capital intensive. |
Top Plays
Watchlist Triggers
Tactical Summary
Read the Directional analysis for MRNA. This AI-generated report covers regime classification, key price levels, strategy recommendations, and actionable trade ideas drawn from end-of-day options data including gamma exposure, delta exposure, and implied volatility.